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**Additional file 1.** Full study protocol.
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CCh conceived the study and led the protocol development. MAR and PRC drafted the initial protocol MAR led the development of the ICF and CRFs, and PRC led the development of the self-assessment questionnaire. AC led the statistical analysis plan. CD and GM led the development of immunology methods. FCT, JRY, BS, MF and GR critically reviewed the clinical and microbiological methods. MG and JSM critically reviewed the pharmaceutical aspects. All authors read and approved the final manuscript.

This study is funded by the Barcelona Institute for Global Health (ISGlobal) and the Clínica Universidad de Navarra (CUN). The placebo was contributed in kind by Idifarma.

The sponsor is a center of a non-for-profit academic institution. Some of the authors of this protocol and those participating in data collection, analysis, interpretation and report are employees of the sponsor.

All data will be available to the research collaborators. Decision to publish rests solely with the researchers. The full data set will be made publicly available not later than six months after trial completion.

Approved by the ethics committee \[Comité de Ética de la Investigación con Medicamentos (CEIm), Hospital Universitario Puerta de Hierro Majadahonda\] on May 5th 2020. Approved by the Spanish Agency of Medicines and Sanitary products on May 7th 2020.

Informed consent will be obtained for all participants.
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